



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/869,741	01/09/2002	Leonard Sciorra	13257.00044	8516
34055	7590	08/22/2006	EXAMINER	
PERKINS COIE LLP POST OFFICE BOX 1208 SEATTLE, WA 98111-1208			DO, PENSEE T	
		ART UNIT	PAPER NUMBER	1641

DATE MAILED: 08/22/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/869,741	SCIORRA ET AL.	
	Examiner	Art Unit	
	Pensee T. Do	1641	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 08 June 2006.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-24 and 26-39 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-24 and 26-39 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____.
3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date <u>10/10/01</u> .	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
	6) <input type="checkbox"/> Other: _____.

DETAILED ACTION

Amendment Entry & Claim status

The amendment filed on June 8, 2006 has been acknowledged and entered.

Claims 1-24, 26-39 are pending.

Withdrawn Rejection(s)

Rejections under 103 in the previous office action are withdrawn herein.

New Grounds of Rejection(s)

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1-9, 12, 14, 16-20, 22-24, 26-29, 37-39 are rejected under 35 U.S.C. 103(a) as being unpatentable over Farber (US 5,602,042) in view of Steindler et al. (US 6,638,763).

Farber teaches a method and apparatus for magnetically separating biological particles from a mixture. The method comprises providing superparamagnetic beads coated with a ligand with specific affinity to target molecules; combining the sample suspected of containing the target molecules with such beads to form a mixture; exposing the mixture to a plate with a collection surface so that the beads flow through the fluid toward the magnetic field source so that the target molecules are collected against the plate surface. The target molecules can be transferred out of the plate from

the fluid by a transfer element. The sample comprises of various cells, proteins, viruses, and other particles, both biological and non-biological. The target molecules can be a population of cells or a subpopulation of a cell type and it is inherent that the undesired components of the sample are the other subpopulations other cells. (see col. 3, lines 1-44). The magnet and the plate are configured to direct the flow of tagged particles to selected portions of the plate surface. For examples, the magnet element can be arranged with the plate element so that the generated magnetic field is stronger at selected areas of the plate surface. The provision of a spatially varying magnetic field enables the device to control the spatial distribution of the cells collected against the plate. The magnet element is positioned vertically above the plate, and couples to the plate at selected locations for providing a stronger magnetic attraction at these locations. Since the magnetic attraction at certain locations are stronger than those at the other locations, the magnetic field must be increased at predetermined strength. (increasing at predetermined magnetic field strength)(col. 3, line 65-col. 4, line 10). Alternatively, the magnet element can be fixed at one point on the periphery of a rotating disc that is disposed vertically above the plate. The rotating disk moves the magnet element relative to the plate to spatially vary the magnetic field. Other configurations for spatially varying the magnetic field can use a distributed array of magnet elements that can be selectively activated and deactivated. (pulsing) (see col. 3, line 59-col. 4, line 11). The device in Figure 1, illustrates a series of posts 30 that allows the strength of the magnetic field to be varied over the area of the surface 42. The magnet control system 14 (fig. 1) selectively activates the posts 30 and thus

generates a spatially-varying and time-varying magnetic field. It is inherent that the activating and deactivating of the magnetic field is performed at a frequency such that the pulses overlap in time since Farber teaches the control system activates and deactivates posts that generates a time-varying magnetic field. The resultant varying magnetic field causes the magnetically-induced movement of the particles and the particles 28 are distributed across the surface of the plate 16 by the selectively activated posts. (see col. 11, lines 20-37; col. 7, lines 35-50). The magnetic particles adhering to the plate can be removed from the plate by deactivating the magnetic field and are collected against a receiver by a transfer system. (see col. 11, lines 44-50). The method also comprises a step of removing the magnetic particles from the target substance (see col. 5, lines 1-9). Although Farber does not explicitly teach that the magnetic particles have uniform physical and magnetic properties, these properties are inherent because Farber teaches that the magnetic particles are superparamagnetic particles, and have a diameter greater than 1 micron. (see col. 4, lines 55-58). The present invention also teaches that the magnetic particles are superparamagnetic and have diameter around 0.05 to 4.5 microns. Thus, since the type and the size of magnetic particles in Farber are the same as those of the present invention, it is inherent that Farber's magnetic particles have uniform physical and magnetic properties and are substantially identical. Farber teaches that that fluid sample can be a liquid sample of a biological material such as sera, that contains a variety of components including cells, proteins or other biological material. The target or desired components can be a specific subpopulation of cells. The moieties on the surface of the particles are antibodies. (see

Art Unit: 1641

col. 9, lines 30-48). A sample of sera contains at least cells and proteins. Thus, when cells are the targets and separated from the sera sample, the proteins must be the undesired portions of the sample. Regarding claim 24, it is inherent that the non-target component migrates at a different rate than that by target which are conjugated to magnetic particles because magnetic particles migrates can migrate at a faster rate due to the magnetic fields being imposed. The magnetic mixture is placed along one edge of the substrate material. (see fig. 1). The magnetic field has a strength that varies substantially linearly with distance within the plane of the substrate. (see col. 3, line 59-col. 4, line 11). For claim 14, Farber teaches that the microbeads can be magnetically responsive particle having an exterior surface coated with a layer of material suitable for absorbing one or more biological protein molecules. (see col. 9, lines 49-52). Regarding claim 23, since Farber teaches target substance is separated from the sample, it is inherent that such target substance is the undesired component of the sample because the concentration of the undesired components in the sample is inversely associated with the concentration of the desired components in the sample. Thus, when the bound and unbound portions of a sample are separated, either portion can be the desired components to be studied and that would leave the other portion undesired.

However, Farber fails to teach placing the suspension of sample and magnetic particles onto a substrate material, wherein the substrate material comprises a viscous solution; the substrate material is methylcellulose and the solution is between 1.7% and 2% methycellulose.

Art Unit: 1641

Steindler teaches methylcellulose as a viscous bioorganic solution which is used for cell separation. Methylcellulose which, by its viscous nature, limits contacts between cells and between cells and a substrate and allows clonal analyses. (see col. 6, lines 10-17).

It would have been obvious to one of ordinary skills in the art to add methylcellulose as taught by Steindler to the suspension of magnetic particles and target of Farber to separate cells and to prevent cells from contacting the substrate (such as unbound magnetic particles, other magnetic particles in the solution, or the bottom of the container holding the suspension) or from aggregating with other cells in the solution. Since methylcellulose solution can form a gel at lower temperature, it can prevent diffusion of the magnetic component unless a magnetic force is applied according to the method of Farber. Regarding claim 27, it would have been obvious to one having ordinary skills in the art at the time the invention was made to use methycellulose at a range of 1.7% to 2 % since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. *In re Aller*, 105 USPQ 233.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 32-36 are rejected under 35 U.S.C. 103(a) as being unpatentable over Farber (US 5,602,042) in view of Steindler.

Farber and Steindler have been discussed above.

However, Farber and Steindler fail to teach the frequency at which the magnetic field is activated or deactivated is from about 0.5 to 10 seconds per pulse or 2.0 second per pulse; a magnetic field strength to be about 1.5 to 2.0 or at least 3.0 Tesla

Since Farber teaches that his magnetic field can be activated or deactivated to flow the magnetic particles across the substrate, it would have been obvious to one having ordinary skills in the art at the time the invention was made to arrive at these specific pulse ranges or magnetic field strength since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. *In re Aller*, 105 USPQ 233.

Claims 10, 11, 13, 15 , 21 and 30 are rejected under 35 U.S.C. 103(a) as being unpatentable over Farber (US 5,602,042) in view of Steindler as applied to claims 1-9, 12, 14, 16-20, 22-24, 29, 37-39 above, and further in view of Terstappen et al. (US 5,646,001).

Farber and Steindler have been discussed above.

However, Farber and Steindler fail to teach that the magnetic particles include at least two different magnetic particles with different physical or electromagnetic properties; wherein the moieties on the surface of the magnetic particles are capture agents that bind to at least one ligand that binds to the target substance; the capture agents bind to more than one ligand; wherein the sample is from maternal blood and the

Art Unit: 1641

desired component is fetal cell and the undesired component is maternal cell. Farber also fails to teach labeling the target substance with a fluorescent marker.

Terstappen teaches a method for separating and releasing one or more selected subset of biological entities from a mixed population. The method comprises providing a plurality of capture agents comprising a receptor which specifically binds, either directly or indirectly, to a solid support to the character determinant of the first subset and at least a second capture agent comprising a receptor which specifically binds, directly or indirectly, to the characteristic determinant of one other subset. The sample is added to the those capture agents. Magnetic field is applied to separate those subsets from the rest of the sample. (see col. 4, line 55-col. 5, line 15). One type of receptor binds to the a highly magnetic bead and another type is bound to a bead with a low magnetic saturation (different beads with different electromagnetic property). Separation in a high gradient magnetic field would capture both types of beads. Removal from the field to a weaker magnetic separation would result in a specific retention of biological substances bound to highly magnetic beads. (see col. 12, lines 54-65). Terstappen also teaches that the specific cell types are fetal cells present in the maternal blood (see example 16, col. 5, line 34). The specific binding substance used are anti-haptens, anti-lectins, peptides, protein A & G, etc. (see col. 7, lines 55). These are the same substances those claimed in the present invention. (see the present specification, page 26, lines 13-20). The method also comprises a step of selective releasing the target cells from the magnetic particles and isolating the released target cells. For detection, the target cells can be linked to a fluorescent label (see col. 19, lines 1-20).

It would have been obvious to one of ordinary skills in the art to use different magnetic particles with different electromagnetic property as taught by Terstappen in the combined method of the Farber and Steindler to separate more than one subset of target substances in a mixed population simultaneously and thus much time and effort can be saved. One skilled in the art would have a reasonable expectation of success when modifying the combined method of Farber using more than one magnetic particles and Steindler with different property because they both teaches varying magnetic field strengths when separating a mixed population of cells and releasing cells from the magnetic particles. It would have been obvious to one of ordinary skills in the art to add a fluorescent label to the released target cells as taught by Terstappen in the method of Farber because Farber also teaches releasing target cells/biological substances after separation for detection. Regarding claim 13, since Terstappen teaches that the ligands for specific binding are the same as those ligands in the present invention and the ligand can bind to the solid phase directly or indirectly, it would have been obvious to one of ordinary skills in the art to use the indirect method of binding specific substances as taught by Terstappen to the magnetic particles of Farber for an indirect affinity binding. Such indirect binding is known for providing high affinity and specificity between the solid phase and the ligand so that the target can be stably captured. Regarding claim 15, since the specific binding substance taught by Terstappen are the same as capture agents of the present invention, it is inherent that the specific binding substance of Terstappen can bind to the more than one ligand, which binds to the target substance in an indirect binding approach. Regarding claim 21, it would have been obvious to one

Art Unit: 1641

of ordinary skills in the art to separate fetal cells and maternal cells since both reference teaches separating cells and maternal cells and fetal cells are often genetically studied.

Claim 31 is rejected under 35 U.S.C. 103(a) as being unpatentable over Farber (US 5,602,042) in view of Steindler as applied to claim 1 above, and further in view of Tseng-Law et al. (US 6,017,719).

Farber and Steindler have been discussed above.

However, Farber and Steindler fail to teach labeling non-target substance with a fluorescent marker.

Tseng-Law teaches a positive or negative methods of cell selection from a heterogeneous cell suspension containing undesired cells having a second antigen. The positive selected cells are labeled with a fluorescent marker. (see abstract; col. 4, lines 40-63; col. 21, line 65-col. 22, line 10).

It would have been obvious to one of ordinary skills in the art to incorporate a step of positive selection and label the non-target selected cells with a fluorescent marker as taught by Tseng-Law in the combined method of Farber and Steindler since the references teach using magnetic particles to separate a heterogeneous mixture of cells so that undesired cells can be confirmed that they are eliminated from the mixture.

Response to Arguments

Applicant's arguments with respect to claims 1-24, 26-39 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Pensee T. Do whose telephone number is 571-272-0819. The examiner can normally be reached on Monday-Friday, 7:00-3:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Pensee T. Do
Patent Examiner
August 17, 2006

Long Le
LONG V. LE 08/18/06
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600